Loading
A US study testing Paxman's machine that cools and squeezes the hands and feet during taxane chemotherapy to prevent nerve damage.
The Dana-Farber study plans 50 participants and lists taxane-induced peripheral neuropathy as its condition, with the Paxman Limb Cryocompression System as the intervention. ClinicalTrials.gov gives an estimated primary completion in August 2027.
Shares Paxman, Limb cryocompression devices for chemotherapy nerve damage (Paxman Neuropathy System, Hilotherm ChemoCare) and the tag machines-wave3.
Shares Limb cryocompression devices for chemotherapy nerve damage (Paxman Neuropathy System, Hilotherm ChemoCare), Paclitaxel / nab-paclitaxel and the tag machines-wave3.
Shares Limb cryocompression devices for chemotherapy nerve damage (Paxman Neuropathy System, Hilotherm ChemoCare) and the tag machines-wave3.
Shares Limb cryocompression devices for chemotherapy nerve damage (Paxman Neuropathy System, Hilotherm ChemoCare), Paclitaxel / nab-paclitaxel and the tag machines-wave3.
Shares Paxman and the tag machines-wave3.
Shares Limb cryocompression devices for chemotherapy nerve damage (Paxman Neuropathy System, Hilotherm ChemoCare) and the tag machines-wave3.
Shares Docetaxel, Paclitaxel / nab-paclitaxel and the tag machines-wave3.
Shares Paxman, Limb cryocompression devices for chemotherapy nerve damage (Paxman Neuropathy System, Hilotherm ChemoCare) and the tag machines-wave3.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/